STOCK TITAN

Adage Capital files Schedule 13G showing 7.67% NextCure (NXTC) ownership

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Adage Capital Management, L.P. and related parties report a significant passive ownership stake in NextCure, Inc. The reporting group, including Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross, reports beneficial ownership of 277,202 shares of NextCure common stock.

This position represents 7.67% of the outstanding common stock, based on 3,612,096 shares outstanding as of May 1, 2026, as referenced from NextCure’s Form 10-Q. The reporting persons have shared voting and dispositive power over all 277,202 shares and no sole voting or dispositive power. The filing is made on a joint basis pursuant to a joint filing agreement.

Positive

  • None.

Negative

  • None.
Shares beneficially owned 277,202 shares Common Stock of NextCure, Inc. reported by the Adage reporting group
Ownership percentage 7.67% Percent of NextCure common stock class beneficially owned by the reporting persons
Shares outstanding 3,612,096 shares NextCure common stock outstanding as of May 1, 2026, from Form 10-Q
Shared voting power 277,202 shares Shares of NextCure common stock over which reporting persons share voting power
Shared dispositive power 277,202 shares Shares of NextCure common stock over which reporting persons share dispositive power
beneficial ownership regulatory
"The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power regulatory
"6 | Shared Voting Power 277,202.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"8 | Shared Dispositive Power 277,202.00"
Schedule 13G regulatory
"Ownership of more than 5 Percent on Behalf of Another Person."
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
investment manager financial
"ACM, as the investment manager of Adage Capital Partners, L.P."

FAQ

What ownership stake in NextCure, Inc. (NXTC) does Adage Capital report?

Adage Capital Management, L.P. and related reporting persons report beneficial ownership of 277,202 shares of NextCure common stock, representing 7.67% of the outstanding shares based on 3,612,096 shares outstanding as of May 1, 2026.

How many NextCure (NXTC) shares are outstanding according to this filing?

The ownership percentage is calculated using 3,612,096 shares of NextCure common stock outstanding as of May 1, 2026, as referenced from NextCure’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

What voting power does Adage Capital have over its NextCure (NXTC) shares?

The reporting persons disclose 0 shares with sole voting power and 277,202 shares with shared voting power. They likewise report 0 shares with sole dispositive power and 277,202 shares with shared dispositive power over NextCure common stock.

Who are the reporting persons in the NextCure (NXTC) Schedule 13G?

The Schedule 13G is filed by Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross, in their respective capacities as managers and general partners of related Adage entities that manage and hold the NextCure shares.

How is beneficial ownership of NextCure (NXTC) structured for Adage?

Beneficial ownership is reported with respect to 277,202 shares held directly by Adage Capital Partners, L.P., for which Adage Capital Management, L.P., and Messrs. Atchinson and Gross have shared voting and dispositive power through various general partner and managing member roles.

Is the Adage group’s stake in NextCure (NXTC) above 5%?

Yes. The reporting persons state their beneficial ownership of 7.67% of NextCure’s common stock, which is above the 5% threshold that triggers a Schedule 13G beneficial ownership filing under SEC rules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





65343E207

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Adage Capital Management, L.P.
Signature:/s/ Robert Atchinson
Name/Title:By: Adage Capital Partners, L.L.C., its General Partner, By: Robert Atchinson, its Managing Member
Date:08/12/2026
Robert Atchinson
Signature:/s/ Robert Atchinson
Name/Title:Robert Atchinson, individually
Date:08/12/2026
Phillip Gross
Signature:/s/ Phillip Gross
Name/Title:Phillip Gross, individually
Date:08/12/2026
Exhibit Information

Exhibit 99.1: Joint Filing Agreement